5 Best NASDAQ 100 Stocks to Buy Other Than SpaceX

3. Amgen Inc. (NASDAQ:AMGN)

On July 7, 2026, Truist raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $340 from $327 as part of a broader Q2 earnings preview for biotech. Truist said it expects a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage. The firm also cited a robust catalyst calendar, sector optimism, and deal activity as drivers of recent momentum across biotech.

On July 8, Morgan Stanley lowered the firm’s price target on Amgen to $333 from $340 and kept an Equal Weight rating on the shares. Morgan Stanley said biotech could benefit from broader market leadership and lower interest rates, noting that historical data shows strong performance in falling rate environments because of the sector’s rate sensitivity.

Last month, Mizuho analyst Salim Syed raised the firm’s price target on Amgen to $303 from $295. Syed updated the company’s model after the Q1 report.

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide.

1281292 - 11759070 - 1